

INFORMATION DISCLOSURE STATEMENT

Applicant : Goddard, et al.
App. No : 10/063,557
Filed : May 2, 2002
For : SECRETED AND
TRANSMEMBRANE POLYPEPTIDES
AND NUCLEIC ACIDS ENCODING
THE SAME
Examiner : David J. Blanchard
Art Unit : 1643

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

October 12, 2005

(Date)

Daniel Hart

Daniel Hart, Reg. No. 40,637

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is an Information Disclosure Statement by Applicant (PTO/SB/08 equivalent) listing twenty-two (22) references to be considered by the Examiner. Also enclosed are fifteen (15) foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing of a Notice of Allowance. This Statement is accompanied by the fees set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

10/17/2005 FMETEK11 00000011 10063557

01 FC:1806

180.00 OP

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Oct. 12, 2005

By: *Daniel Hart*

Daniel Hart

Registration No. 40,637

Attorney of Record

Customer No. 30,313

(619) 235-8550



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Multiple sheets used when necessary)	Application No.	10/063,557
	Filing Date	May 2, 2002
	First Named Inventor	Goddard, et al.
	Art Unit	1643
SHEET 1 OF 2	Examiner	David J. Blanchard
	Attorney Docket No.	GNE.3230R1C39


U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	6,156,500	12-05-2000	Falb, D.	
	2	6,162,604	12-19-2000	Jacob, Chaim O.	
	3	6,228,582 B1	05-08-2001	Rodier, et al.	
	4	6,395,306 B1	05-28-2002	Cui, et al.	
	5	6,414,117 B1	07-02-2002	Levinson, D. A.	
	6	6,465,185 B1	10-15-2002	Goldfine, et al.	
	7	6,562,343 B1	05-13-2003	Levinson, D. A.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
	8	WO 97/38085	10-16-1997	California Pacific Medical Center		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	9	ALBERTS, et al. 1994. <i>Molecular Biology of the Cell</i> , 3rd Edition, pp. 403-404, 453. New York: Garland Publishing.	
	10	ALBERTS, et al. 1994. <i>Molecular Biology of the Cell</i> , 3rd Edition, pp. 1216-1217. New York: Garland Publishing.	
	11	ALLMAN, et al. 1996. BCL-6 expression during B-cell activation. <i>Blood</i> , 87(12):5257-5268.	

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Multiple sheets used when necessary) SHEET 2 OF 2	Application No.	10/063,557
	Filing Date	May 2, 2002
	First Named Inventor	Goddard, et al.
	Art Unit	1643
	Examiner	David J. Blanchard
	Attorney Docket No.	GNE.3230R1C39

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	12	ANDERSON, et al. 1997. A comparison of selected mRNA and protein abundances in human liver. <i>Electrophoresis</i> , 18:533-537.	
	13	CHEN, et al. 2002. Discordant protein and mRNA expression in lung adenocarcinomas. <i>Molecular & Cellular Proteomics</i> 1.4, pp. 304-313.	
	14	FESSLER, et al. 2002. A genomic and proteomic analysis of activation of the human neutrophil by lipopolysaccharide and its mediation by p38 mitogen-activated protein kinase. <i>The Journal of Biological Chemistry</i> , 277(35):31291-31302.	
	15	FU, et al. 1996. Translational regulation of human p53 gene expression. <i>The EMBO Journal</i> , 15(16):4392-4401.	
	16	HANCOCK, W. S. 2004. Do we have enough biomarkers? <i>Journal of Proteome Research</i> , 3(4):685.	
	17	KONOPKA, et al. 1986. Variable expression of the translocated <i>c-abl</i> oncogene in Philadelphia-chromosome-positive B-lymphoid cell lines from chronic myelogenous leukemia patients. <i>Proc. Natl. Acad. Sci. USA</i> , 83:4049-4052.	
	18	LEWIN, B. 1994. Oncogenes: Gene expression and cancer, Chap. 39, pp. 1196-1201. <i>Genes V</i> . New York: Oxford University Press.	
	19	OHARA, et al. 2001. Directional cDNA library construction assisted by the <i>in vitro</i> recombination reaction. <i>Nucleic Acids Research</i> , 29(4):e22 p. 1-8.	
	20	TOKUNAGA, et al. 2000. Application of quantitative RT-PCR using "TaqMan" technology to evaluate the expression of CK 18 mRNA in various cell lines. <i>J. Exp. Clin. Cancer Res.</i> , 19(3):375-381.	
	21	WANG, et al. 1996. mRNA Differential display: Application in the discovery of novel pharmacological targets. <i>Trends Pharmacol. Sci.</i> , 17(8):276-279.	
	22	2002-2003 Catalog & Technical Reference, New England BioLabs, Inc., p. 122.	

1986156:dmb
101105

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.